期刊文献+

胃肠间质瘤45例临床诊治体会 被引量:2

Diagnosis and treatment of gastrointestinal stromal tumor: an analysis of 45 cases
下载PDF
导出
摘要 目的探讨胃肠道间质瘤(GIST)的诊断和治疗。方法对我院2001年12月至2006年5月收治的45例临床资料完整GIST患者的临床表现、治疗方法及病理结果进行回顾性分析。结果45例均行手术治疗,其中良性5例(11.1%),潜在恶性13例(28.9%),恶性27例(60.0%),免疫组织化学Ⅲ型跨膜蛋白酪氨酸激酶生长因子受体蛋白(CD)117、CD34阳性表达均为24例(93.3%)。23例获随访,随访时间5~64个月,其中3例死亡,1例出现肝转移。结论GIST缺乏特异性临床表现,术前确诊率低,多以黑便、腹痛和腹部肿块为主要症状;治疗上以手术治疗为主,术后辅以酪氨酸激酶抑制剂治疗具有较好疗效。 Objective To explore the diagnosis and treatment of gastrointeretinal stromal tumor (GIST). Methods Forty-five patients with GIST were enrolled from December 2001 to May 2006. Results Forty-five cases were given surgical treatment. 5 cases were proved to be benign tumor( 11.1% ), 13 eases were latent malignant tumor (28.9 % ) and 27 cases (60%) were malignant tumor in the post-operation pathology. Immunohistochemistry revealed that the positive rate of CDll7 and CD34 were 93.3% and 93.3% respectively. 23 cases were followed up from 5 to 64 months. 3 cases died and one had liver metastasis. Conclusion GIST is lack of specific clinic symptoms and pro-operation diagnostic rate is relatively low. However, dark stools, stomachache and abdominal mass are main symptoms and signs. The patients have better therapy effects with surgery and tyrosine kinase inhibitors.
作者 曹先东
出处 《中国医药》 2009年第2期150-152,共3页 China Medicine
关键词 胃肠道间质瘤 手术治疗 酪氨酸激酶抑制剂 Gastrointestinal stromal tumor Surgical treatment Tyrosine kinase inhibitors
  • 相关文献

同被引文献23

  • 1杜春燕,师英强,傅红,赵广法,周烨,蔡国响.胃肠道间质瘤103例预后分析[J].中国实用外科杂志,2007,27(4):297-299. 被引量:49
  • 2DeMatteo RP,Lewis JJ,Leung D,et al.Two hundred gastrointestinal stromal tumors:recurrence patterns and prognostic factors for survival.Ann Surg,2000,231 (1):51-58.
  • 3Blanke CD,Demetri GD,von Mehren M,et a1.Long-term results from a randomized phase II trial of standard-versus higher-dose Gleevec mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT[J].J Clin Oncol,2008,26(4):620-625.
  • 4Katz SC,DeMatteo RP.Gastrointestinal stromal tumors and leiomyosarcomas[J].J Surg Oncol,2008,97(4):350-359.
  • 5Nilsson B,Bumming P,Kindblom M,et al.Gastrointestinal stromal tumors:The incidence,prevalence,clinical course and prognostication the preimatinib mesylate era:A population based study in western Sweden[J].Cancer,2005,103(4):821-829.
  • 6Mussi C,Ronellenfitsch U,Jakob J,et al.Post-imatinib surgery in advanced/metastatic GIST:is it worthwhile in all patients[J].Ann Oncol,2010,21(2):403-408.
  • 7Maluccio MA,Covey AM,Schubert J,et al.Treatment of metastatic sarcoma to the liver with bland embolization[J].Cancer,2006,107(7):1617-1623.
  • 8Mavligit GM,Zukwiski AA,Ellis LM,et al.Gastrointestinal leiomyo sarcoma metastatic to the liver.Durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastine[J].Cancer,1995,75 (8):2083-2088.
  • 9Van Osterom AT,Judson I,Verwei J,et al.Safety and efficacy of imatinib in metastatic gastrointestinal stromal tumors:a phase I study[J].Lancet,2001,358(9291):1421-1423.
  • 10Blanke CD,Rankin C,Demetri GD,et al.Phase III randomized,intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase:s0033[J].J Clin Oncol,2008,26(4):626-632.

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部